ESTRO 2024 - Abstract Book

S1666

Clinical - Lung

ESTRO 2024

Fig. 1. A) PET/CT scan before FM placement and SBRT. B) Contrast-Enhanced CT for treatment planning after FM. C) Treatment plan with isodose distribution. D) CT scan after SBRT--> complete response. E) Fiducial markers implanted into the tumor

Tab.1. Intrafractional tumor shifts due to tumor motion and resulting changes in PTV size (ΔPTV) using an ITV -based strategy.

Conclusion:

EBUS-implanted FM is a minimally invasive and well tolerated procedure which may mitigate the impact of tumor motion on SBRT delivery to mediastinal lymphnodes. Use of an ablative schedule resulted in a high local control rate. Careful pre-treatment assessment, including bronchoscopy at the time of FM implant is required before SBRT, particularly for mediastinal organ infiltration involvement which may result in fatal adverse events. Patients receiving fiducial-guided SBRT with RTTT to mediastinal lymphadenopathies are currently enrolled in a prospective observational trial at our Institution (FLUXUS).